CCR2 and neoplasm: Phenotype analysis determined that once the cells derived from CCR2+HSCs reach intracranial tumor after intravenous injection, they upregulate markers associated with antigen presenting cells, including CD11c, MHC-II, and CD80 (Fig. 4b).